Subscribe to RSS
DOI: 10.1055/s-2006-949621
Photolabile Peptide Nucleic Acid Monomers: Synthesis and Photodeprotection
Publication History
Publication Date:
09 August 2006 (online)
Abstract
The photolabile 2-(2-nitrophenyl)propyloxy carbonyl (NPPOC) group has been introduced as an amino protecting group for peptide nucleic acids (PNA) to be used as building blocks in photolithographic solid-phase PNA synthesis. NPPOC-protected PNA derivatives undergo fast light-promoted deprotection with high per step coupling efficiency.
Key words
solid-phase synthesis - genomics - DNA - protecting groups - photolabile
-
1a
Egholm M.Buchardt O.Christensen L.Behrens C.Freier SM.Driver DA.Berg RH.Kim SK.Norden B.Nielsen PE. Nature (London) 1993, 365: 566 -
1b
Nielsen PE.Egholm M.Berg RH.Buchardt O. Science 1991, 254: 1497 -
2a
Ray A.Norden B. FASEB J. 2000, 14: 1041 -
2b
Cetojevic-Simin D.Dimitar J.Jasminka M.Visnja B.Vesna K.Ljiljana A.Gordana B. Arch. Oncol. 2001, 9: 33 - 3
Weiler J.Gausepohl H.Hauser N.Jensen ON.Hoheisel JD. Nucleic Acids Res. 1997, 25: 2792 - 4
Pirrung MC.Wang L.Montague-Smith MP. Org. Lett. 2001, 3: 1105 -
5a
Fodor SPA.Read JL.Pirrung MC.Stryer L.Lu AT.Solas D. Science 1991, 251: 767 -
5b
Pease AC.Solas D.Sullivan EJ.Cronin MT.Holmes CP.Fodor SPA. Proc. Natl. Acad. Sci. U.S.A. 1984, 91: 5022 -
6a
Lipshutz RJ.Fodor SPA.Gingeras TR.Lockhart DJ. Nat. Genet. 1999, 21: 20 -
6b
Ramsay G. Nat. Biotechnol. 1998, 16: 40 -
6c
Gershon D. Nature (London) 2002, 416: 885 - 7
Singh-Gasson S.Green RD.Yue Y.Nelson C.Blattner F.Sussman MR.Cerrina F. Nat. Biotechnol. 1999, 17: 974 -
8a
Ohtsuka E.Tanaka T.Tanaka S.Ikehara M. J. Am. Chem. Soc. 1978, 100: 4580 -
8b
McCray JA.Herbette L.Kihara T.Trentham DR. Proc. Natl. Acad. Sci. U.S.A. 1980, 77: 7237 -
8c
Nerbonne JM.Richard S.Nargeot J.Lester HA. Nature (London) 1984, 310: 74 -
8d
Liu ZC.Shin DS.Lee KT.Jun BH.Kim YK.Lee YS. Tetrahedron 2005, 61: 7967 - 9
Bhushan KR.DeLisi C.Laursen RA. Tetrahedron Lett. 2003, 44: 8585 - 10
Atwell GJ.Denny WA. Synthesis 1984, 1032 - 11
Fader LD.Boyd M.Tsantrizos YS. J. Org. Chem. 2001, 66: 3372 - 12
Will DW.Breipohl G.Langner D.Knolle J.Uhlmann E. Tetrahedron 1995, 51: 12069 -
13a
Dueholm KL.Egholm M.Behrens C.Christensen L.Hansen HF.Vulpius T.Petersen KH.Berg RH.Nielsen PE.Buchardt O. J. Org. Chem. 1994, 59: 5767 -
13b
Coull JM,Egholm M,Hodge RP,Ismail M, andRajur SB. inventors; US Patent 6 133 444. - 14
Puschl A.Sforza S.Haaima G.Dahl O.Nielsen PE. Tetrahedron Lett. 1998, 39: 4707 - 16
McGall HG.Barone AD.Diggelmann M.Fodor SPA.Gentalen E.Ngo N. J. Am. Chem. Soc. 1997, 119: 5081 - 18
Stewart JM.Young JD. Solid Phase Peptide Synthesis Pierce Chemical Co.; Rockford IL: 1984.
References and Notes
Spectroscopic Data for Selected Compounds.
Compound 4: 1H NMR (400 MHz, CDCl3): δ = 7.66 (d, J = 8.0 Hz, 1 H, ArH), 7.51 (t, J = 7.4 Hz, 1 H, ArH), 7.41 (d, J = 7.6 Hz, 1 H, ArH), 7.30 (t, J = 7.8 Hz, 1 H, ArH), 6.14 (s, 1 H, NH), 4.05-4.25 (m, 2 H, CH2), 3.59 (m, 1 H, CH), 3.42 (t, J = 5.2 Hz, 2 H, CH2), 3.25 (br s, 1 H, NH2), 3.10 (t, J = 5.6 Hz, 2 H, CH2), 2.94 (br s, 1 H, NH2), 1.26 (d, J = 6.8 Hz, 3 H, CH3). MS (API-ES+): m/z = 268.1 [M + H+], 290.1 [M + Na+], 306.0 [M + K+].
Compound 5: 1H NMR (400 MHz, CDCl3): δ = 7.72 (d, J = 8.0 Hz, 1 H, ArH), 7.54 (t, J = 7.4 Hz, 1 H, ArH), 7.45 (d, J = 7.6 Hz, 1 H, ArH), 7.31 (t, J = 7.8 Hz, 1 H, ArH), 5.09 (s, 1 H, NH), 4.02-4.21 (m, 2 H, CH2), 4.09 (q, J = 7.2 Hz, 2 H, CH2), 3.70 (m, 1 H, CH), 3.38 (s, 2 H, CH2), 3.20 (t, J = 5.2 Hz, 2 H, CH2), 2.76 (t, J = 5.6 Hz, 2 H, CH2), 2.21 (br s, 1 H, NH), 1.27 (d, J = 6.8 Hz, 3 H, CH3), 1.21 (t, J = 7.0 Hz, 3 H, CH3). MS (API-ES+): m/z = 354.1 [M + H+], 376.1 [M + Na+], 392.1 [M + K+].
Compound 6a: 1H NMR (400 MHz, CDCl3): δ = 8.52 and 8.50 (2 s, 1 H, NH), 7.67 (d, J = 8.0 Hz, 1 H, ArH), 7.52 (t, J = 7.4 Hz, 1 H, ArH), 7.43 (d, J = 7.6 Hz, 1 H, ArH), 7.30 (t, J = 7.8 Hz, 1 H, ArH), 7.01 and 6.98 (2 s, 1 H, CH), 5.63 and 5.05 (2 s, 1 H, NH), 4.38 and 4.32 (2 s, 2 H, CH2), 4.03-4.20 (m, 2 H, CH2), 4.08 (q, J = 7.2 Hz, 2 H, CH2), 4.01 (s, 2 H, CH2), 3.64 (m, 1 H, CH), 3.50 (t, J = 5.2 Hz, 2 H, CH2), 3.32 (t, J = 5.6 Hz, 2 H, CH2), 1.89 (s, 3 H, CH3), 1.35 (d, J = 6.8 Hz, 3 H, CH3), 1.25 (t, J = 7.0 Hz, 3 H, CH3). MS (API-ES+): m/z = 520.1 [M + H+], 542.1 [M + Na+], 558.1 [M + K+].
Compound 7a: 1H NMR (400 MHz, CDCl3): δ = 9.81 and 9.79 (2 br s, 1 H, NH), 7.70 (d, J = 8.0 Hz, 1 H, ArH), 7.54 (t, J = 7.4 Hz, 1 H, ArH), 7.45 (d, J = 7.6 Hz, 1 H, ArH), 7.33 (t, J = 7.8 Hz, 1 H, ArH), 7.06 and 7.01 (2 s, 1 H, CH), 5.88 and 5.39 (2 s, 1 H, NH), 4.40 and 4.38 (2 s, 2 H, CH2), 4.07-4.25 (m, 2 H, CH2), 4.02 (s, 2 H, CH2), 3.62 (m, 1 H, CH), 3.49 (t, J = 5.2 Hz, 2 H, CH2), 3.35 (t, J = 5.6 Hz, 2 H, CH2), 1.82 and 1.80 (2 s, 3 H, CH3), 1.32 (d, J = 6.8 Hz, 3 H, CH3). MS (API-ES+): m/z = 492.1 [M + H+], 514.1 [M + Na+], 530.0 [M + K+].
In a typical procedure to attach photolabile PNA to an amino-glass slide, NPPOC-T was attached to the amino-glass slide mounted in a flow cell by activation of the carboxyl groups of NPPOC-T (14.7 mg, 0.03 mmol) in DMF (0.25 mL). After 20 min, excess NPPOC-T was flushed out with MeCN and specific areas (pixels) were irradiated at 365 nm in MeCN using DMD for varying period of time to remove the photolabile protecting groups at specific locations. The amino groups exposed by this treatment were visualized by being covalently coupled to a BODIPY dye (100 µg) in DMF (0.25 mL) for 10 min followed by scanning on a GenPix Scanner.